During the annual congress of the European Society of Cardiology (ESC) 2017 in Barcelona the new guidelines on the management of valvular heart disease (VHD) were presented and simultaneously published in the European Heart Journal [1] . Numerous new data published since 2012 in the field of VHD badly required an update of recommendations. The guidelines are again a joint document established by the ESC and European Association of Cardio-Thoracic Surgery (EACTS). This is of particular importance considering the potential area of conflict arising from rapidly evolving new catheter techniques for the treatment of VHD competing with surgical treatment.
A completely new format was chosen for this document. In order to meet the needs of the users the guideline document was kept short mainly focusing H. Baumgartner, MD ( ) Division of Adult Congenital and Valvular Heart Disease, Dept. of Cardiovascular Medicine, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany helmut.baumgartner@ukmuenster.de on recommendations for evaluation and management of VHD. For more background information the document is linked to the freely accessible chapter on VHD of the ESC textbook which was simultaneously updated by the same task force.
In the general comments, new sections on risk stratification, the concept of heart valve centers and treatment of atrial fibrillation (AF) in patients with VHD were added. The increasing complexity of patient evaluation and treatment decisions as well as surgical and catheter interventional procedures requires highly specialist multidisciplinary teams, special equipment and sufficiently high volumes to provide optimal VHD patient care. Recommended requirements of a heart valve center are specified in the document. More details are provided in a separate ESC/EACTS position paper [2] .
Based on subgroup analyses of four large randomized trials it is now recommended that non-vitamin K antagonist oral anticoagulants should be considered in patients with AF and aortic valve disease, mitral regurgitation and aortic bioprosthetic valves after the third month of implantation. They are not recommended in mitral stenosis and contraindicated in patients with mechanical valves. In patients who undergo valve surgery, surgical ablation of AF should be considered in patients with symptomatic AF and may be considered in those with asymptomatic AF. Surgical excision or external clipping of the left atrial appendage may be considered in patients undergoing valve surgery.
In aortic regurgitation (AR) decision making for surgery is still primarily based on symptoms, left ventricular (LV) size and function as well as dilation of the ascending aorta. New data confirm that patients with TGFBR1 and TGFBR2 mutations (including Loeys-Dietz syndrome) are at increased risk of aortic complications. This led to the recommendation that surgery should be considered even for aortic diameters ≥45 mm regardless of the presence of additional risk factors (in contrast to Marfan's syndrome where the cut-off in patients without risk factors remains at 50 mm). There is more emphasis now on valve repair and valve sparing aortic root surgery. In patients with pliable non-calcified tricuspid or bicuspid valves who have either aortic root enlargement with normal cusp motion (type I mechanism of AR) or cusp prolapse (type II mechanism) heart team discussion is strongly recommended with respect to valve repair as a feasible alternative to valve replacement. In young patients with aortic root dilation and tricuspid aortic valves, aortic valve repair, using the re-implantation or remodelling with aortic root annuloplasty technique, is recommended, when performed by experienced surgeons (class I level of evidence C recommendation, IC).
The diagnosis of severe aortic stenosis (AS) has become increasingly more challenging over recent years with the introduction of new entities, such as lowflow, low-gradient AS with reduced LV ejection fraction (EF), low-flow, low-gradient AS with preserved LVEF and even normal flow, low-gradient AS. The new guidelines acknowledge the clinical needs and address this issue with a special section recommending an integrated approach adapted from the position paper of the European Association of Cardiovascular Imaging and the American Society of Echocardiography published earlier this year [3] . In short, the most difficult patients remain those with low-gradient AS and either reduced EF but no flow reserve or with preserved LVEF. In these patients an integrative approach considering clinical criteria (symptoms without other explanation, old age), qualitative criteria (LV hypertrophy or reduced longitudinal function without other explanation) and quantitative criteria (mean gradient, valve area, low flow confirmed by other means, such as 3D echocardiography, computed tomography [CT], magnetic resonance imaging or invasively derived data, and in particular the degree of aortic valve calcification by CT [calcium scoring]).
With respect to indications for interventions in symptomatic patients with low-flow, low-gradient AS with reduced LVEF but absence of flow reserve (no significant increase in transvalvular flow with dobutamine stress) the guidelines now recommend that intervention (considering the less invasive alternative of transcatheter valve implantation, TAVI) should be considered particularly when CT calcium scoring confirms severe AS. Otherwise there is little change in the indications for intervention in asymptomatic patients.
In asymptomatic patients with severe AS, based on new data the indications for surgery in patients with markedly elevated brain natriuretic peptide (BNP) levels have been upgraded from IIb (may be considered) to IIa (should be considered) when plasma levels are equal or greater than three times the age and sexcorrected normal range and in those with severely elevated pulmonary systolic pressure at rest (systolic pressure >60 mmHg) if each is confirmed by repeated measurements and without other explanations.
On the other hand, previous recommendations regarding interventions based on an exercise increase in mean transaortic gradient >20 mm Hg or with excessive LV hypertrophy have been removed based on currently available data.
The recommendations for the mode of valve implantation, surgical versus transcatheter, are probably the most controversial issue in the guideline document. Most importantly, the document emphasizes shared decision making by a heart valve team including cardiologists and cardiac surgeons as well as the need for a department of cardiac surgery on site at centers performing TAVI. This is based on safety reasons, the high degree of complexity in both decision making and management of these patients, volume dependence of outcome and resource dependency indicating centralization of care.
Surgical aortic valve replacement (SAVR) remains the preferred approach in patients at low surgical risk. It is emphasized that the definition of low risk relies not only on currently available risk scores with all their limitations in this context (Euroscore II and Society of Thoracic Surgeons [STS] score <4%, Euroscore I < 10%) but also includes the absence of other established risk factors, such as frailty, porcelain aorta, and sequelae of chest radiation. Patients who are not at low risk by this definition should be carefully evaluated by the heart team weighing up individual risks and benefits for each modality. The TAVI procedure is clearly recommended in patients not suitable, or at prohibitive risk for SAVR, as assessed by the heart valve team unless severe comorbidities suggest that TAVI is unlikely to improve quality of life or survival.
In patients who are not at low surgical risk by the above definition, careful evaluation by the heart team is necessary weighing individual risks and benefits for each modality, favoring TAVI in elderly patients suitable for transfemoral access. Aspects that need to be considered in the individual decision process include: (1) clinical characteristics (Favors SAVR: STS/ EuroSCORE II <4%, age <75 years and suspicion of endocarditis; Favors TAVI: STS/EuroSCORE ≥4%, presence of severe comorbidities not adequately reflected by scores, age ≥75 years, previous cardiac surgery, frailty and restricted mobility that may affect the rehabilitation process). (2) Anatomical and technical aspects (Favors SAVR: unfavorable access for TAVI, short distance between coronary ostia and annulus, annulus size out of recommended range for TAVI, unfavorable aortic root or valve morphology, bicuspid, degree and pattern of calcification, presence of thrombi in aorta or LV; Favors TAVI: favorable access for transfemoral TAVI, favorable root, valve and annulus morphology, sequelae of chest radiation, porcelain aorta, presence of intact coronary bypass grafts, ex-
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The 2017 ESC/EACTS guidelines on the management of valvular heart disease 169 review article pected patient-prosthesis mismatch and severe chest deformation or scoliosis) and (3) other cardiac conditions: consideration of concomitant interventions, such as coronary artery disease requiring revascularization (interventional or surgical), severe mitral or tricuspid regurgitation, aneurysm of the ascending aorta or septal hypertrophy requiring myectomy.
Finally, local experience and outcome data for both modalities must be taken into consideration. The core principle in this approach is to emphasize a complex decision-making process with a list of specific factors to be considered in each patient, rather than defining broad patient groups that should either undergo TAVI or SAVR. In an individual patient, the relevance of each listed characteristic differs depending on the presence of other characteristics. For example, TAVI may still be a good choice despite suboptimal anatomical characteristics for intervention if surgical risk is high. Conversely, with a lower surgical risk, TAVI would be preferred only if patient characteristics suggested an optimal result with that approach. In particular, the ability to perform TAVI from a transfemoral approach is important. Similarly, patient age and life expectancy determine the relevance of concerns with TAVI, such as limited durability data, higher pacemaker implantation rates and paravalvular regurgitation.
For primary mitral regurgitation (MR) there are no major changes in the recommendations. In asymptomatic patients with severe MR but without significant LV dilatation, with normal LV function, sinus rhythm and no pulmonary hypertension the guidelines remain restrictive even if repair appears feasible at low operative risk. There are still no convincing data demonstrating a benefit of surgery in this subgroup. In addition, new studies comparing echocardiography and magnetic resonance imaging (MRI) raise concerns that echocardiography tends to overestimate MR severity. Only in patients with a flail leaflet or severely dilated left atrium despite sinus rhythm (≥60 ml/m 2 ) should surgery already be considered at LV end-systolic diameters between 40 and 44 mm. The IIb recommendation that surgery may be considered in asymptomatic patients with no other indications but increase in systolic pulmonary pressure above 60 mm Hg during exercise was taken out. No further studies have supported the prognostic value beyond rest pulmonary artery pressure. In addition, it remains unclear from available data at which exercise level this cut-off should not be reached.
For secondary mitral regurgitation it is emphasized that neither for surgery nor for catheter interventional treatment of MR could a survival benefit be demonstrated so far. For this reason, the recommendations must remain restrictive. In addition, it is emphasized that the difference in thresholds currently defining severe MR for secondary versus primary MR (regurgitant orifice area ≥20 versus ≥40 mm 2 , regurgitant volume ≥30 versus ≥60 ml) must be viewed with particular concern when considering the indications for isolated interventions on MR. These thresholds for secondary MR have been defined because of their association with a worse outcome, only; however, it is unclear if the prognosis is independently affected by MR compared to LV dysfunction and whether reduction of MR can improve this prognosis. Mitral valve surgery is still recommended for severe secondary MR at the time of surgical revascularization (IC recommendation). The recommendation that surgery should also be considered with revascularization when MR is moderate had to be taken out since a randomized trial could show no benefit. When there is no option for revascularization, mitral valve surgery or when the surgical risk is increased, transcatheter edge-to-edge repair may be considered if LVEF is greater than 30% in patients who remain symptomatic despite optimal medication treatment including cardiac rechronisation therapy (CRT) if indicated (IIbC). If in this setting LVEF is <30%, the heart team may consider intervention after careful evaluation for ventricular assist devices or heart transplantation according to individual patient characteristics.
Little has changed with respect to mitral stenosis and tricuspid valve disease. In tricuspid regurgitation (TR), recommendations are now even more clearly separated for primary and secondary TR. In patients who undergo left-sided valve surgery, tricuspid valve repair should be considered liberally. The indications comprise not only severe TR but also mild and moderate TR if the tricuspid annulus is ≥ 40 mm (≥21 mm/m 2 body surface area) in diameter (IIa) or when a history of recent right heart failure is present (IIb).
In isolated severe TR, patients respond well to diuretic therapy, which may delay timely intervention before the right ventricular (RV) myocardium becomes irreversibly damaged resulting in high operative risk and poor improvement of outcome with intervention. Consideration of surgery should therefore not only be driven by symptoms but by progressive RV dilatation and deterioration of RV function in mildly symptomatic or asymptomatic severe TR.
The major changes in the management of patients with prosthetic heart valves can be summarized as follows: the not uncommon detection of, mostly subclinical thrombosis of biological valve cups, both surgically implanted and even more frequently affected, transcatheter heart valves by computed tomography led to new discussions about the optimal antithrombotic treatment. The phenomenon was much less frequently seen under oral anticoagulation than under platelet inhibitors. There seems to be less concern with respect to thromboembolic events than with the occurrence of cusp mobility and gradient increase up to severe stenosis, which may however be reversible under oral anticoagulation. Oral anticoagulation (OAC) is therefore recommended as first line treatment for bioprosthetic valve thrombosis. The currently available data however do not justify chang- 170 The 2017 ESC/EACTS guidelines on the management of valvular heart disease K review article ing the general recommendations for antithrombotic treatment after surgical and transcatheter implantation of biological valves. Further research is required and the positive effect on valve thrombosis (the clinical relevance of subclinical thrombosis remains currently unclear) must be weighed against an increased bleeding risk with OAC. In aortic bioprostheses the preferred treatment during the first 3 months still remains aspirin (IIa versus IIb for OAC). It is however recommended to assess baseline hemodynamics by echocardiography and repeat these measurements routinely every year.
Recommendations for the antithrombotic therapy after TAVI are particularly difficult at present and results of ongoing randomized trials must be awaited before stronger recommendations can be made. So far, dual antiplatelet therapy (DAPT) should be considered for 3-6 months and monotherapy may be considered when the risk of bleeding is high. In patients with mechanical valves and associated atherosclerosis the addition of low dose aspirin to OAC had to be reduced from IIa (should be considered) to IIb (may considered) because of new data. If patients can perform it adequately, international normalized ratio (INR) self-management is recommended (IB). The antithrombotic management of patients who undergo percutaneous coronary intervention has been adapted from the 2017 ESC Focused Update on Dual Antiplatelet Therapy (DAPT; [4] ). Ischemic risk has to be carefully weighed against the individual bleeding risk. If concerns about ischemic risk prevail, up to 6 months of triple therapy, dual therapy up to 12 months (OAC plus one antiplatelet agent) and OAC only thereafter should be considered. If concerns about bleeding risk prevail, depending on the individual risk, either 1 month of triple therapy, dual therapy up to 12 months and OAC thereafter or dual therapy (OAC plus one antiplatelet agent) from the beginning should be considered. Because of the mechanical non-vitamin K antagonists are contraindicated in this setting.
In cases of prosthetic valve dysfunction two recommendations are new: in patients with bioprosthetic valve dysfunction the heart team should consider transcatheter valve dysfunction as an alternative to re-operation depending on surgical risk, valve type and valve size. In patients with significant paravalvular regurgitation and high operative risk, the heart team may consider catheter interventional treatment.
In conclusion, new data on the diagnosis and management of valvular heart disease published since 2012 when the previous practice guidelines of the ESC and the EACTS were presented allowed important new recommendations to be made, particularly for the use of catheter interventional treatment, indications for intervention in asymptomatic patients, medical treatment and organization of care. Nevertheless, quite a number of gaps in the evidence remain and should stimulate further research.
